Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Thomas Jens Ettrich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7654-2442; OpenAlex author ID A5010810595, A5069481844. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
92
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 33

  1. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  2. Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). Co-author DOI 10.1038/s41416-025-03188-x↗
  3. Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach. Co-author DOI 10.14740/gr2132↗
  4. Organoid-based precision medicine in pancreatic cancer. Co-author DOI 10.1002/ueg2.12701↗
  5. PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancr… Co-author DOI 10.1007/s10637-025-01526-7↗
  6. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  7. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  8. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  9. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  10. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  11. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Last author DOI 10.1016/j.annonc.2022.09.161↗
  12. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  13. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  14. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  15. Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Co-author DOI 10.1159/000521631↗
  16. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. First author DOI 10.3390/cancers14010217↗
  17. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14041074↗
  18. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  19. Systemic Therapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s11864-021-00895-4↗
  20. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  21. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2633↗
  22. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Co-author DOI 10.3390/cancers13112539↗
  23. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  24. Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. Last author DOI 10.1159/000497291↗
  25. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). First author DOI 10.21037/tgh.2019.03.05↗
  26. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  27. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  28. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  29. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Co-author DOI 10.18632/oncotarget.23330↗
  30. Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature. Co-author DOI 10.1055/s-0043-105502↗
  31. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-016-2052-4↗
  32. [Therapy in pancreatic cancer - and still it moves along!]. Co-author DOI 10.1055/s-0041-101154↗
  33. Pancreatic Cancer: Progress in Systemic Therapy. First author DOI 10.1159/000380785↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Theodor Werner Seufferlein · 19 shared papers, 2014–2026 · strength 2.59
  2. Lukas Perkhofer · 13 shared papers, 2014–2025 · strength 1.56
  3. Volker Kunzmann · 10 shared papers, 2018–2026 · strength 1.35
  4. Jens Thomas Siveke · 9 shared papers, 2018–2026 · strength 1.26
  5. Volker Heinemann · 9 shared papers, 2018–2026 · strength 1.23
  6. Stefan Hubert Boeck · 9 shared papers, 2018–2026 · strength 1.23
  7. Alexander Kleger · 9 shared papers, 2018–2025 · strength 1.22
  8. Frank Kullmann · 8 shared papers, 2018–2026 · strength 1.12
  9. Hana Algül · 8 shared papers, 2018–2026 · strength 1.01
  10. Alica K. Beutel · 6 shared papers, 2019–2025 · strength 0.89
  11. Anke Reinacher‐Schick · 7 shared papers, 2018–2025 · strength 0.83
  12. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  13. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76
  14. Johann Gout · 5 shared papers, 2020–2025 · strength 0.75
  15. Dirk Waldschmidt · 5 shared papers, 2021–2026 · strength 0.74
  16. Brigitte Kimmel · 4 shared papers, 2022–2026 · strength 0.67
  17. Friedrich Anger · 4 shared papers, 2022–2026 · strength 0.67
  18. Marko Kornmann · 5 shared papers, 2018–2025 · strength 0.54
  19. Manfred Paul Lutz · 3 shared papers, 2023–2026 · strength 0.53
  20. Uwe Pelzer · 4 shared papers, 2021–2024 · strength 0.53
  21. Hans Armin Kestler · 4 shared papers, 2021–2025 · strength 0.52
  22. Michael Geißler · 5 shared papers, 2016–2024 · strength 0.47
  23. Niklas Sturm · 2 shared papers, 2022 · strength 0.46
  24. Andreas Wolfgang Berger · 6 shared papers, 2016–2022 · strength 0.46
  25. Andrea Tannapfel · 4 shared papers, 2018–2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.